PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Phase 3 Recruiting 12 enrolled Alexion Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

Timeline

Start: 2024-11-13
Primary completion: 2026-12-15
Completion: 2029-01-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefurulimab	Monoclonal antibody	—	Subcutaneous

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Summary

Timeline

Drugs

Indications